Translational Infrastructure
BioCyto Labs has invested in specialised translational nanoparticle engineering infrastructure supporting advanced formulation development for CNS therapeutic delivery applications.
This includes commissioning of a climate-controlled electrohydrodynamic atomisation (EHDA/electrospraying) system designed to support experimental optimisation of nanoparticle architectures under tightly regulated environmental conditions relevant to translational formulation engineering.
The platform supports investigation of:
Nanoparticle size regulation
Dispersity optimisation
Formulation stability
Encapsulation performance
Biologically relevant delivery behaviour
within advanced CNS-focused delivery system workflows.
BioCyto’s platform incorporates experimentally informed nanoparticle engineering workflows including serum-relevant stability assessment, BBB-relevant endothelial systems, TEER analysis, and physicochemical nanoparticle characterisation.
Technical Foundations
Internal CNS Delivery Platform Developed Since 2018
Multi-year CNS nanoparticle engineering programme
Climate-controlled EHDA/electrospraying infrastructure
BBB-relevant endothelial systems
TEER and metabolic flux analysis workflows
Comparative nanoparticle architecture evaluation
Translational formulation optimisation